NBIX Neurocrine Biosciences Inc.

71.34
-1.67  -2%
Previous Close 73.01
Open 72.43
Price To Book 14.44
Market Cap 6469266864
Shares 90,682,182
Volume 1,360,964
Short Ratio
Av. Daily Volume 1,162,967

SEC filingsSee all SEC filings

  1. 8-K - Current report 181230037
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181160075
  3. 8-K - Current report 181159940
  4. 8-K - Current report 181083579
  5. S-8 - Securities to be offered to employees in employee benefit plans 181032364

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2018.
NBI-74788
Congenital Adrenal Hyperplasia (CAH) - children
Phase 2a data due 1Q 2019.
NBI-74788
Congenital Adrenal Hyperplasia (CAH) - adults
Approval for sNDA 80 mg capsules announced October 5, 2017.
INGREZZA
Tardive dyskinesia
Phase 2 planned.
NBI-640756
Essential Tremor
NDA filing planned for 2Q 2019.
Opicapone
Parkinson's disease
Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.
INGREZZA - T-Force GOLD
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
INGREZZA
Tourette syndrome - adults
Phase 3 data released February 21, 2018 - primary endpoint met. Second Phase 3 trial also met primary endpoint - March 13, 2018.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
Approved April 11, 2017.
INGREZZA
Tardive dyskinesia
Phase 2 data due late-2019.
INGREZZA - T-Force PLATINUM
Tourette syndrome - pediatric

Latest News

  1. Do Options Traders Know Something About Neurocrine Biosciences (NBIX) Stock We Don't?
  2. Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Synergy Pharmaceuticals
  3. Why Under Armour, Neurocrine Biosciences, and XPO Logistics Slumped Today
  4. Why Neurocrine Biosciences Is Tanking
  5. Why Neurocrine Biosciences Stock Is Plummeting Today
  6. Neurocrine Biosciences says trial of Tourette syndrome treatment missed primary goal
  7. Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome
  8. Should You Buy Neurocrine Biosciences, Inc. (NBIX)?
  9. See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
  10. 3 Top Biotech Stocks to Buy Right Now
  11. Edited Transcript of NBIX earnings conference call or presentation 5-Nov-18 9:30pm GMT
  12. Neurocrine (NBIX) Catches Eye: Stock Jumps 6.5%
  13. Today's Research Reports on Trending Tickers: Neurocrine Biosciences and Amarin
  14. AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
  15. 5 Pharma Stocks to Stay Away From
  16. Report: Developing Opportunities within Louisiana-Pacific, Neurocrine Biosciences, Tahoe Resources, Loews, Quotient Technology, and Evolent Health — Future Expectations, Projections Moving into 2018
  17. Neurocrine Biosciences to Present at the Jefferies 2018 London Healthcare Conference
  18. Does Neurocrine Biosciences Inc’s (NASDAQ:NBIX) Debt Level Pose A Problem?
  19. Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates

SEC Filings

  1. 8-K - Current report 181230037
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181160075
  3. 8-K - Current report 181159940
  4. 8-K - Current report 181083579
  5. S-8 - Securities to be offered to employees in employee benefit plans 181032364
  6. 8-K - Current report 18991773
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18982072
  8. 8-K - Current report 18981620
  9. 8-K - Current report 18966345
  10. CT ORDER - Confidential treatment order 18880313